Understanding how changes in genome structure contribute to acute myeloid leukemia
Dysregulated genome architecture in acute myeloid leukemia
This study is looking at how changes in DNA and gene patterns might contribute to acute myeloid leukemia (AML), with a special focus on certain genes that are important for healthy blood cells, to help find new ways to treat the disease.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11013883 on NIH RePORTER |
What this research studies
This research investigates the role of altered genome organization and epigenetic patterns in the development of acute myeloid leukemia (AML). By analyzing DNA methylation and gene expression in AML cells, the study aims to uncover the relationships between genetic mutations and changes in genome architecture. The researchers are particularly focused on the HOX gene loci, which are crucial for maintaining normal blood cell function and are disrupted in AML. Through comprehensive analysis of primary AML samples, the study seeks to identify specific genetic interactions that may lead to new therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia.
Not a fit: Patients with other types of leukemia or those without a diagnosis of acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights and treatments for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in understanding the genetic and epigenetic factors in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Spencer, David H — Washington University
- Study coordinator: Spencer, David H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.